by Anne
QUESTION: My friend has had type 1 diabetes for 10 years and is doing well. Who should consider a pancreas transplant, can it remove the need for insulin permanently, and is there encouraging news about stem-cell treatment?
A successful pancreas or islet transplant can restore insulin production and may allow someone with type 1 diabetes to stop insulin for a period. However, it is not a simple or guaranteed permanent cure. Whole-pancreas transplantation is major surgery, and both pancreas and donor-islet recipients generally need long-term immunosuppressive medicine. These treatments are reserved mainly for kidney failure or recurrent severe hypoglycemia, ketoacidosis, or disabling glucose instability despite optimized specialist care.
Answer by Dr. Albana Greca, MD, MMedSc
Hi Anne,
It is encouraging that your friend is doing well. For someone whose type 1 diabetes is safely controlled with insulin, CGM, and modern diabetes technology, transplant risks usually outweigh the possible benefit.
A donated pancreas contains beta cells that can produce insulin. When the graft works, glucose may return to near-normal levels and insulin injections may no longer be required. The recipient still needs lifelong transplant follow-up and anti-rejection treatment.
A transplant does not erase the history of type 1 diabetes. The graft can be rejected, autoimmune damage may recur, or the pancreas may eventually fail. Insulin may therefore be needed again.
A specialist team first reviews diabetes education, insulin delivery, CGM, automated insulin delivery, and prevention of severe lows. Our type 1 diabetes guide explains current daily care.
A whole-pancreas transplant is major abdominal surgery. Islet transplantation is different: insulin-producing islets from a deceased donor are infused into the portal vein and settle in the liver. It is not a partial-pancreas operation.
In the United States, the donor-islet product Lantidra is approved only for selected adults unable to approach their HbA1c goal because of repeated severe hypoglycemia despite intensive management and education. Some recipients stop insulin, while others still need it or lose graft function later.
There is no guaranteed duration. A functioning pancreas graft may provide insulin independence for many years, but outcomes differ by procedure, rejection, infection, blood-vessel complications, and adherence to immunosuppressive medicine.
Donor-islet results also vary. Some recipients remain insulin-independent for years; others need reduced insulin, require another infusion, or never stop insulin. Preventing severe hypoglycemia may be the main goal.
The old claim that one or two of every ten recipients die is not an appropriate universal estimate. Risk varies by health, procedure, center, kidney disease, and cardiovascular status. A transplant team must assess the individual balance of benefit and harm.
Successful transplantation can normalize glucose and may prevent, slow, or sometimes improve certain complications. It does not guarantee that established kidney, eye, nerve, or cardiovascular damage will disappear. It is not a routine treatment for neuropathy alone.
Screening remains important after transplantation. Read more about diabetes complications and prevention.
Stem-cell-derived islet therapy is promising. Scientists can now produce insulin-secreting islet cells from stem cells and transplant them into selected participants.
In an early zimislecel study, most full-dose participants produced insulin and became insulin-independent at one year. However, the study was small, recipients required immunosuppression, serious adverse events occurred, and long-term durability remains unknown. The treatment is in phase 3 research but is not an approved routine stem-cell cure.
Encapsulated and gene-edited cells that might avoid lifelong immunosuppression are also being studied. These approaches remain experimental. Avoid clinics selling unapproved stem-cell “cures,” which may be ineffective or dangerous.
If she is doing well without severe hypoglycemia or kidney failure, she should continue specialist care rather than pursue transplantation solely to avoid insulin. Modern insulin treatment, CGM, pumps, and automated insulin delivery can improve safety without transplant risks.
If she has recurrent severe lows, impaired awareness of hypoglycemia, repeated ketoacidosis, or advanced kidney disease, her endocrinologist can refer her to an accredited transplant center.
Never stop insulin while waiting for a transplant or after reading about stem-cell research. Without adequate insulin, type 1 diabetes can quickly cause diabetic ketoacidosis. Seek urgent care for vomiting, abdominal pain, rapid breathing, confusion, dehydration, high ketones, or persistently very high glucose.
Pancreas and islet transplantation can be life-changing for carefully selected people, but they exchange insulin treatment for surgery, rejection risk, and immunosuppression. A person with stable type 1 diabetes and no severe complications is generally not an appropriate candidate. Stem-cell-derived islets are promising but remain investigational.
Educational safety note: This answer is for general diabetes education only. It does not replace personal medical advice or transplant evaluation. Do not stop or change insulin, immunosuppressive medicines, diet, or other treatment without speaking with the responsible healthcare team.
Last reviewed: July 2026.
Click here to post comments or follow up
Ask the Doctor now? Simply click here to return to Type 1 diabetes information.